With AMA Category III CPT Code for 3D Breast Ultrasound Tomography
The Company’s first CPT code becomes effective January 1, 2027, enables billing and opening new commercial opportunities with hospital accounts
QT Imaging Holdings, Inc., a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced that the American Medical Association (AMA) CPT (Current Procedural Terminology) Editorial Panel has approved a new Category III CPTTM code for 3D quantitative transmission volumetric ultrasound tomography of the breast.
The new Category III code, X579T, represents a significant milestone in the clinical and commercial advancement of QT Imaging’s technology, recognizing the distinct clinical service enabled by its radiation-free, compression-free, 3D breast imaging platform. The new CPT code ensures standardized reporting of this emerging imaging service, supporting data collection, utilization tracking and continued evaluation by clinicians, payers and health systems. The code is scheduled for release on July 1, 2026, with an effective date of January 1, 2027.
“Approval of our first CPT code is a meaningful validation of both the technology and its clinical foundation and significantly enhances our commercial strategy in particular to prospective hospital accounts,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “This milestone reflects years of rigorous development, clinical engagement, and collaboration with the medical community. It is an important step toward expanding access to a safer, more comfortable breast imaging option that complements existing modalities and supports better-informed clinical decision making.”
Category III CPT codes are established by the AMA to track emerging technologies and services that demonstrate clinical relevance and growing adoption. Acceptance of a Category III code signals acknowledgment by the CPT Editorial Panel that a technology represents a distinct and reportable clinical service, and is a major step on the pathway toward broader reimbursement and adoption.
“We plan to continue working closely with clinical partners, professional societies and regulatory stakeholders to advance adoption of our technology, as well as to pursue additional CPT codes,” Dr. Dinu added.
QT Imaging’s system uses advanced ultrasound tomography to produce true 3D volumetric images of the breast without ionizing radiation or painful compression. The technology is designed to provide quantitative, reproducible information that can be particularly valuable in women with dense breast tissue, while improving the overall patient experience.
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (Nasdaq: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience.
